GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Catheter Precision Inc (AMEX:VTAK) » Definitions » Long-Term Debt & Capital Lease Obligation

Catheter Precision (Catheter Precision) Long-Term Debt & Capital Lease Obligation : $0.10 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Catheter Precision Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Catheter Precision's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Catheter Precision's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Catheter Precision's Total Assets for the quarter that ended in Dec. 2023 was $30.74 Mil. Catheter Precision's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2023 was 0.00.

Catheter Precision's LT-Debt-to-Total-Asset increased from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that Catheter Precision is progressively becoming more dependent on debt to grow their business.


Catheter Precision Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Catheter Precision's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catheter Precision Long-Term Debt & Capital Lease Obligation Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial 2.89 3.84 1.98 - 0.10

Catheter Precision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.09 0.14 0.12 0.10

Catheter Precision Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Catheter Precision  (AMEX:VTAK) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Catheter Precision's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.097/30.736
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Catheter Precision Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Catheter Precision's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Catheter Precision (Catheter Precision) Business Description

Traded in Other Exchanges
Address
1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc Formerly Ra Medical Systems Inc is a commercial-stage medical device company whose business comprises of the design, manufacture and sale of new medical technologies in the field of cardiac electrophysiology, or EP. Its product, View into Ventricular Onset System or VIVO System which is a non invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. . It operates business as one segment which includes all activities related to the marketing, sales and development of medical technologies in the field of cardiac EP.
Executives
David A Jenkins director, officer: Executive Chairman of Board P.O. BOX 682838, PARK CITY UT 84068
Steven K Passey officer: Chief Financial Officer 3216 SOUTH HIGHLAND DRIVE, SUITE 200, SALT LAKE CITY UT 84117
James Joseph Caruso director 28 FIRST AVE, SEASIDE PARK NJ 08752
Brian Conn officer: Chief Financial Officer MICROISLET, INC., 6370 NANCY RIDGE DRIVE, SUITE 112, SAN DIEGO CA 92121
Andrew C. Jackson officer: CFO & Secretary 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Susanne Meline director P.O. BOX 515381, #86506, LOS ANGELES CA 90051
Martin J Colombatto director
Richard Jr Mejia director 2200 FARADAY AVENUE, SUITE 100, CARLSBAD CA 92008
William R Enquist director 11810 WILLS ROAD, ALPHARETTA GA 30009
Joan Stafslien director CAREFUSION CORPORATION, 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Daniel Horwood officer: General Counsel C/O RA MEDICAL SYTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Jeffrey J Kraws officer: Co-President 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Dean Irwin director, 10 percent owner, officer: See Remarks C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Martin Burstein 10 percent owner C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011